(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Robert Motzer discussing updated data from the CheckMate 214 trial with 5-years of follow-up. The combination of nivolumab + ipilimumab is approved by the European Commission and the US FDA for first-line treatment of patients with advanced RCC with IMDC intermediate/poor risk disease, based on superior overall survival (OS) and objective response rate (ORR) over sunitinib in the randomized, phase 3 CheckMate 214 trial.1 Conditional survival, used to predict sustained treatment benefit, accounts for time since treatment initiation and provides improved prognostic information at landmark time points. Conditional survival in advanced RCC patients was estimated in CheckMate 214 with a minimum 5-years of follow-up (median follow-up, 67.7 months).

X